KAMAU THERAPEUTICS
LIVE

Serial Number

98128117

Owner

Kamau Therapeutics, Inc.

Attorney

Connie Ellerbach

Filing Date

Aug 11, 2023

Add to watchlist:

No watchlists yet
View on USPTO

KAMAU THERAPEUTICS Trademark

Serial Number: 98128117

KAMAU THERAPEUTICS is a trademark filed by Kamau Therapeutics, Inc. on August 11, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Kamau Therapeutics, Inc. (2 trademarks)

200 East Grand Avenue
South San Francisco, CA 94080

Entity Type: 03

Trademark Details

Filing Date

August 11, 2023

Registration Date

Not Registered

Published for Opposition

August 13, 2024

Goods & Services

Pharmaceutical preparations for the treatment of genetic diseases and disorders; pharmaceutical preparations in the nature of genetically modified cells for use in the treatment of genetic diseases and disorders; pharmaceutical preparations for detecting genetic predispositions for medical purposes; pharmaceutical preparations for gene therapy, gene editing, genome editing, and targeted gene replacement and insertion; cell therapy products in the nature of genetically modified cells for the treatment of genetic diseases and disorders; gene therapy products in the nature of genetically engineered human genes for the treatment of genetic diseases and disorders; pharmaceutical preparations for non-genotoxic conditioning to enable engraftment; pharmaceutical preparations containing templates of DNA sequences to restore and normalize the function in a disease-causing gene; gene edited and corrected human cells for medical use

Pharmaceutical research and development services; Research in the fields of pharmaceuticals, gene regulation, gene modification, gene correction, cell therapy, gene therapy, genetic diseases and disorders, and templates containing DNA sequences, and targeted gene replacement and insertion; Gene editing, namely, medical and scientific research for the treatment of genetic diseases and disorders; research and development of therapeutics pharmaceuticals using gene editing; providing medical and scientific research information in the field of pharmaceuticals, gene regulation, gene modification, gene correction, cell therapy, gene therapy, genetic diseases and disorders, and templates containing DNA sequences, and targeted gene replacement and insertion; research in the field of clustered regularly interspaced short palindromic repeats (CRISPR) and homology directed repair (HDR) technologies

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 11, 2026 EXRA
SOU EXTENSION 3 GRANTED
Mar 10, 2026 EX3G
SOU EXTENSION 3 FILED
Mar 10, 2026 EXT3
SOU TEAS EXTENSION RECEIVED
Mar 10, 2026 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 1, 2025 EXRA
SOU EXTENSION 2 GRANTED
Oct 1, 2025 EX2G
SOU EXTENSION 2 FILED
Oct 1, 2025 EXT2
SOU TEAS EXTENSION RECEIVED
Oct 1, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 28, 2025 EXRA
SOU EXTENSION 1 GRANTED
Mar 27, 2025 EX1G
SOU EXTENSION 1 FILED
Mar 27, 2025 EXT1
SOU TEAS EXTENSION RECEIVED
Mar 27, 2025 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Oct 8, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 13, 2024 NPUB
PUBLISHED FOR OPPOSITION
Aug 13, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 24, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 5, 2024 CNSA
EXAMINER'S AMENDMENT ENTERED
Jun 26, 2024 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jun 26, 2024 GNEN
EXAMINERS AMENDMENT E-MAILED
Jun 26, 2024 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jun 26, 2024 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 21, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 21, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 21, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Apr 17, 2024 GNRN
NON-FINAL ACTION E-MAILED
Apr 17, 2024 GNRT
NON-FINAL ACTION WRITTEN
Apr 17, 2024 CNRT
ASSIGNED TO EXAMINER
Apr 12, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 11, 2023 NWOS
NEW APPLICATION ENTERED
Aug 15, 2023 NWAP